CareDx (CDNA) Set to Announce Earnings on Thursday

Posted by Brenda Bartman on Oct 27th, 2026

CareDx (NASDAQ:CDNA – Get Free Report) is anticipated to release its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to announce earnings of $0.2548 per share and revenue of $121.95 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

CareDx (NASDAQ:CDNA – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.37 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.14. CareDx had a return on equity of 2.87% and a net margin of 24.23%. The firm had revenue of $131.95 million during the quarter, compared to analysts’ expectations of $114.05 million. During the same quarter last year, the business posted ($0.16) EPS. The firm’s quarterly revenue was up 52.2% compared to the same quarter last year. On average, analysts expect CareDx to post $0.47 EPS for the current fiscal year and $0.63 EPS for the next fiscal year.

CareDx Trading Down 0.2%

Shares of CDNA stock opened at $69.10 on Tuesday. The company has a market capitalization of $3.57 billion, a price-to-earnings ratio of 33.38 and a beta of 2.38. The firm has a 50-day moving average price of $57.62 and a 200 day moving average price of $32.49. CareDx has a twelve month low of $14.23 and a twelve month high of $72.71.

Wall Street Analysts Forecast Growth

CDNA has been the subject of a number of analyst reports. Zacks Research lowered shares of CareDx from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 2nd. BTIG Research lifted their target price on shares of CareDx from $60.00 to $74.00 and gave the stock a “buy” rating in a research note on Thursday, September 24th. William Blair raised CareDx to a “hold” rating in a research note on Thursday, July 16th. Canaccord Genuity Group raised their price objective on CareDx from $65.00 to $80.00 and gave the stock a “buy” rating in a report on Monday, October 19th. Finally, Craig Hallum upgraded CareDx from a “hold” rating to a “buy” rating and set a $64.00 price objective on the stock in a report on Monday, August 3rd. Three research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, CareDx presently has a consensus rating of “Hold” and a consensus price target of $57.00.

Get Our Latest Analysis on CDNA

Insiders Place Their Bets

In related news, Director George Bickerstaff, III sold 20,000 shares of CareDx stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $46.28, for a total value of $925,600.00. Following the transaction, the director owned 134,061 shares in the company, valued at approximately $6,204,343.08. This trade represents a 12.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christine Cournoyer sold 16,000 shares of the business’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $46.94, for a total value of $751,040.00. Following the sale, the director directly owned 42,943 shares of the company’s stock, valued at approximately $2,015,744.42. This trade represents a 27.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.40% of the stock is currently owned by company insiders.

CareDx Company Profile

(Get Free Report)

CareDx, Inc is a healthcare diagnostics company focused on improving the care of organ-transplant patients. The company develops and commercializes noninvasive tests and digital tools intended to help physicians assess transplant-organ health, identify potential rejection, and support long-term patient management.

Its offerings include AlloSure donor-derived cell-free DNA tests for monitoring transplant recipients, AlloMap gene-expression testing for heart-transplant patients, and HeartCare, which combines AlloMap and AlloSure results.